Zobrazeno 1 - 10 of 29 pro vyhledávání: '"Mitsugu Yamamoto"'
1
Akademický článek
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
Autor: Naoki Niikura, Takashi Yamanaka, Hironori Nomura, Kazuhiro Shiraishi, Hiroki Kusama, Mitsugu Yamamoto, Kazuo Matsuura, Kenichi Inoue, Sachiko Takahara, Shosuke Kita, Miki Yamaguchi, Tomoyuki Aruga, Nobuhiro Shibata, Akihiko Shimomura, Yuri Ozaki, Shuji Sakai, Yoko Kiga, Tadahiro Izutani, Kazuhito Shiosakai, Junji Tsurutani
Publikováno v: npj Breast Cancer, Vol 9, Iss 1, Pp 1-8 (2023)
Abstract Therapeutic options for breast cancer patients with brain metastases (BM)/leptomeningeal carcinomatosis (LMC) are limited. Here, we report on the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor rec
Externí odkaz: https://doaj.org/article/c3642081dad641a4a155413b957498c2
Zobrazit plný text záznamu
2
Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region
Autor: Nobumoto Tomioka, Kanako C. Hatanaka, Dai Okuyama, Ken-ichi Watanabe, Mitsugu Yamamoto, Hideki Maeda, Hanae Tachikawa, Sayuri Kuwahara, Ai Shimizu, Hiroaki Suzuki, Yutaka Hatanaka, Masato Takahashi
Publikováno v: Breast Cancer. 30:497-505
Background The efficacy of pre-operative systemic treatment (PST) combined with immune checkpoint inhibition (ICI) for triple-negative breast cancer (TNBC) has been recognized recently as being independent of the degree of programmed death ligand-1 (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::933f255f1c1ad073653dcd80d60af1c7
https://doi.org/10.1007/s12282-023-01442-9
Zobrazit plný text záznamu
5
Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer
Autor: Yuko Minoura, Masato Takahashi, Hideki Maeda, Sayuri Kuwahara, Hanae Tachikawa, Mitsugu Yamamoto, Nobumoto Tomioka, Kenichi Watanabe, Akihiro Sakurai
Publikováno v: Breast Cancer. 29:808-813
When considering BRCA1/2 genetic testing for diagnosis of hereditary breast and ovarian cancer (HBOC), family history (FH) of breast and ovarian cancer is commonly considered. However, FH of other HBOC-related cancers, such as prostate, pancreatic, a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77bc890e1eea57ab8f0801c8f8250232
https://doi.org/10.1007/s12282-022-01360-2
Zobrazit plný text záznamu
9
Abstract P1-07-13: Obesity is associated with poor prognosis of Japanese breast cancer, especially in ER positive/HER2 negative subtype, which tendency is prominent
Autor: Mitsugu Yamamoto, N Tomioka, M Sato, Hideki Maeda, S Terai, H Tachikawa, Masato Takahashi, Kenichi Watanabe
Publikováno v: Cancer Research. 78:P1-07
Introduction: Body mass index (BMI) is defined as a poor prognostic factor in breast cancer patients in western countries. Since the percentage of the overweight differs between Asian and western breast cancer patients, we do not know if breast cance
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f3e99addbfb6ef23f45f226aa0cdd295
https://doi.org/10.1158/1538-7445.sabcs17-p1-07-13
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje